



WISCONSIN

\$3,361,437

Funding for AR Activities
Fiscal Year 2023

One local CDC-supported fellow

Regional Lab for the AR Lab Network
(Midwest)

FUNDING TO HEALTH DEPARTMENTS



\$1,669,257

AR Laboratory Network Regional Lab: Regional labs boost state and local testing capacity and technology to detect, support response to, and prevent AR threats across the nation—and inform innovations to detect AR.

Wisconsin provides AR core testing and surge capacity for AR Lab Network regional and state labs while supporting the Midwest Region. Wisconsin also provides reference testing for *Streptococcus pneumoniae*. Wisconsin's collaborations display flexibility across the AR Lab Network to adapt and support the Network nationally.



\$718,634

Rapid Detection & Response: State, territory, and local public health partners fight AR in health care, the community, and food.

CDC-funded HAI/AR Programs form a network of health departments that detect, prevent, respond to, and contain HAI/AR threats and promote appropriate use of antibiotics and antifungals. CDC's AR Lab Network provides nationwide lab capacity to rapidly detect AR and inform local prevention and response activities to stop the spread of antimicrobial-resistant germs and protect people.



\$120,293

Food Safety projects protect communities by rapidly identifying antimicrobial-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.

Wisconsin uses whole genome sequencing to track local outbreaks of *Listeria*, *Salmonella*, *Campylobacter*, *Shigella*, and *Escherichia coli*, identifies AR genes, and shares surveillance data with PulseNet. When outbreaks are detected, local CDC-supported epidemiologists respond to stop their spread.

The AR Investment Map includes data from CDC's largest funding categories for AR. It represents extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations. See the fiscal year 2023 AR Investment Map Supplemental Funding Fact Sheet for more information.

AR: antimicrobial resistance
COVID-19: coronavirus disease 2019
HAI: healthcare-associated infection
IPC: infection prevention and control

NHSN: National Healthcare Safety Network
STD: sexually transmitted disease
STI: sexually transmitted infection



\$853,253

Drug-resistant Gonorrhea Detect & Respond Program works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities. Only one recommended treatment option remains for gonorrhea and resistance to other antibiotics continues to grow. Strengthening the U.S. Response to Resistant Gonorrhea (SURRG) conducts rapid testing and quick responses to antimicrobial-resistant gonorrhea cases in high-burden communities. SURRG awardees established a state-level antimicrobial-resistant gonorrhea Center of Excellence, developed a state-level gonorrhea treatment failure reporting portal and outbreak response plan, and piloted molecular testing to look for markers of gonorrhea resistance.

The AR Investment Map includes data from CDC's largest funding categories for AR. It represents extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations. See the fiscal year 2023 AR Investment Map Supplemental Funding Fact Sheet for more information.

Page 2 of 2

AR: antimicrobial resistance
COVID-19: coronavirus disease 2019
HAI: healthcare-associated infection
IPC: infection prevention and control

NHSN: National Healthcare Safety Network
STD: sexually transmitted disease
STI: sexually transmitted infection

CDC provides critical support in the U.S. and abroad to protect people from antimicrobial resistance.

ARinvestments.cdc.gov



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention